CytoDyn to Submit Newly Completed Topline Report of CD12 Trial Results to Regulatory Agencies in Multiple Countries including India and Philippines
18 mai 2021 06h00 HE
|
CytoDyn Inc.
Finalized data analysis shows CD12 trial reached almost all of its major secondary endpoints in a subpopulation (62 patients) of critically ill COVID-19 VANCOUVER, Washington, May 18, 2021 (GLOBE...
CytoDyn to Hold Webcast on May 18 to Discuss FDA’s Statement on Leronlimab
17 mai 2021 19h44 HE
|
CytoDyn Inc.
VANCOUVER, Washington, May 17, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a...
CytoDyn Signs Distribution Agreement with Macleods Pharmaceuticals Ltd. to Pursue EUA and Compassionate Use Access to Leronlimab in India
13 mai 2021 08h56 HE
|
CytoDyn Inc.
Macleods is one of the largest pharmaceutical companies in India with presence in over 140 countries VANCOUVER, Washington, May 13, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn”...
CytoDyn’s Leronlimab Featured on OneNews in Philippines on May 9
07 mai 2021 06h00 HE
|
CytoDyn Inc.
Drs. Pourhassan, Recknor, Seethamraju and Nicolas will appear in a one-hour segment beginning at 5:00 pm PT / 8:00 pm ET, Sunday, May 9 VANCOUVER, Washington, May 07, 2021 (GLOBE NEWSWIRE) --...
CytoDyn Reaches Agreement with Albert Einstein Israelite Hospital in Brazil to Conduct Two COVID-19 Trials - a Small Trial in Critically Ill and a Large Trial in Severe Populations
05 mai 2021 03h35 HE
|
CytoDyn Inc.
Interim analysis for critically ill population will be conducted when enrollment reaches about 120 patients or 40% of the approximate 300 patients VANCOUVER, Washington, May 05, 2021 (GLOBE...
CytoDyn to Hold Webcast on May 5 to Provide Update on Multiple Initiatives
03 mai 2021 09h05 HE
|
CytoDyn Inc.
VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a...
Data from 10 Patients with Stage Four Cancer Treated with Leronlimab for Nearly One Year Will Serve as Basis for Pre-Breakthrough Therapy Designation Meeting with FDA
03 mai 2021 09h02 HE
|
CytoDyn Inc.
VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), a...
CytoDyn HIV Indication Update: Leronlimab HIV Extension Arm Nearing 7 Years with Continued Excellent Safety Results
03 mai 2021 09h00 HE
|
CytoDyn Inc.
Following the successful conclusion of three clinical trials, approximately 120 patients continue treatment with leronlimab in extension arms VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) --...
CytoDyn’s Chief Medical Officer Dr. Scott Kelly to Present at Triple Negative Breast Cancer Drug Development Digital Summit 2021 on April 28
27 avr. 2021 16h01 HE
|
CytoDyn Inc.
VANCOUVER, Washington, April 27, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140),...
CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants
22 avr. 2021 23h52 HE
|
CytoDyn Inc.
Company Achieves Total Financing in April of $57 Million VANCOUVER, Washington, April 22, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage...